A review of 65 years of human adenovirus seroprevalence
Introduction: Human adenovirus (HAdV)-derived vectors have been used in numerous pre-clinical and clinical trials during the last 40 years. Current research in HAdV-based vaccines focuses on improving transgene immunogenicity and safety. Because pre-existing humoral immunity against HAdV types corre...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2019-06-01
|
| Series: | Expert Review of Vaccines |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/14760584.2019.1588113 |
| _version_ | 1797680346663223296 |
|---|---|
| author | Franck J. D. Mennechet Océane Paris Aline Raissa Ouoba Sofia Salazar Arenas Sodiomon B. Sirima Guy R. Takoudjou Dzomo Amidou Diarra Isidore T Traore Dramane Kania Karsten Eichholz Eric A. Weaver Edouard Tuaillon Eric J. Kremer |
| author_facet | Franck J. D. Mennechet Océane Paris Aline Raissa Ouoba Sofia Salazar Arenas Sodiomon B. Sirima Guy R. Takoudjou Dzomo Amidou Diarra Isidore T Traore Dramane Kania Karsten Eichholz Eric A. Weaver Edouard Tuaillon Eric J. Kremer |
| author_sort | Franck J. D. Mennechet |
| collection | DOAJ |
| description | Introduction: Human adenovirus (HAdV)-derived vectors have been used in numerous pre-clinical and clinical trials during the last 40 years. Current research in HAdV-based vaccines focuses on improving transgene immunogenicity and safety. Because pre-existing humoral immunity against HAdV types correlate with reduced vaccine efficacy and safety, many groups are exploring the development of HAdV types vectors with lower seroprevalence. However, global seroepidemiological data are incomplete. Areas covered: The goal of this review is to centralize 65 years of research on (primarily) HAdV epidemiology. After briefly addressing adenovirus biology, we chronical HAdV seroprevalence studies and highlight major milestones. Finally, we analyze data from about 50 studies with respect to HAdVs types that are currently used in the clinic, or are in the developmental pipeline. Expert opinion: Vaccination is among the most efficient tools to prevent infectious disease. HAdV-based vaccines have undeniable potential, but optimization is needed and antivector immunity remains a challenge if the same vectors are to be administrated to different populations. Here, we identify gaps in our knowledge and the need for updated worldwide epidemiological data. |
| first_indexed | 2024-03-11T23:28:40Z |
| format | Article |
| id | doaj.art-3b515a34335f43b8b00f2bfd2d120724 |
| institution | Directory Open Access Journal |
| issn | 1476-0584 1744-8395 |
| language | English |
| last_indexed | 2024-03-11T23:28:40Z |
| publishDate | 2019-06-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Expert Review of Vaccines |
| spelling | doaj.art-3b515a34335f43b8b00f2bfd2d1207242023-09-20T10:18:04ZengTaylor & Francis GroupExpert Review of Vaccines1476-05841744-83952019-06-0118659761310.1080/14760584.2019.15881131588113A review of 65 years of human adenovirus seroprevalenceFranck J. D. Mennechet0Océane Paris1Aline Raissa Ouoba2Sofia Salazar Arenas3Sodiomon B. Sirima4Guy R. Takoudjou Dzomo5Amidou Diarra6Isidore T Traore7Dramane Kania8Karsten Eichholz9Eric A. Weaver10Edouard Tuaillon11Eric J. Kremer12University of Montpellier - CNRSUniversity of Montpellier - CNRSUniversity of Montpellier - CNRSUniversity of Montpellier - CNRSCentre National de Recherche et de Formation sur le PaludismeComplexe Hospitalo Universitaire « Le Bon Samaritain »Centre National de Recherche et de Formation sur le PaludismeCentre MurazCentre MurazUniversity of Montpellier - CNRSUniversity of Nebraska-Lincoln, School of Biological SciencesINSERM - University of Montpellier - Establishment Français du Sang - Centre Hospitalier Universitaire de MontpellierUniversity of Montpellier - CNRSIntroduction: Human adenovirus (HAdV)-derived vectors have been used in numerous pre-clinical and clinical trials during the last 40 years. Current research in HAdV-based vaccines focuses on improving transgene immunogenicity and safety. Because pre-existing humoral immunity against HAdV types correlate with reduced vaccine efficacy and safety, many groups are exploring the development of HAdV types vectors with lower seroprevalence. However, global seroepidemiological data are incomplete. Areas covered: The goal of this review is to centralize 65 years of research on (primarily) HAdV epidemiology. After briefly addressing adenovirus biology, we chronical HAdV seroprevalence studies and highlight major milestones. Finally, we analyze data from about 50 studies with respect to HAdVs types that are currently used in the clinic, or are in the developmental pipeline. Expert opinion: Vaccination is among the most efficient tools to prevent infectious disease. HAdV-based vaccines have undeniable potential, but optimization is needed and antivector immunity remains a challenge if the same vectors are to be administrated to different populations. Here, we identify gaps in our knowledge and the need for updated worldwide epidemiological data.http://dx.doi.org/10.1080/14760584.2019.1588113adenovirusvaccinationgene therapyimmunologyseroepidemiology |
| spellingShingle | Franck J. D. Mennechet Océane Paris Aline Raissa Ouoba Sofia Salazar Arenas Sodiomon B. Sirima Guy R. Takoudjou Dzomo Amidou Diarra Isidore T Traore Dramane Kania Karsten Eichholz Eric A. Weaver Edouard Tuaillon Eric J. Kremer A review of 65 years of human adenovirus seroprevalence Expert Review of Vaccines adenovirus vaccination gene therapy immunology seroepidemiology |
| title | A review of 65 years of human adenovirus seroprevalence |
| title_full | A review of 65 years of human adenovirus seroprevalence |
| title_fullStr | A review of 65 years of human adenovirus seroprevalence |
| title_full_unstemmed | A review of 65 years of human adenovirus seroprevalence |
| title_short | A review of 65 years of human adenovirus seroprevalence |
| title_sort | review of 65 years of human adenovirus seroprevalence |
| topic | adenovirus vaccination gene therapy immunology seroepidemiology |
| url | http://dx.doi.org/10.1080/14760584.2019.1588113 |
| work_keys_str_mv | AT franckjdmennechet areviewof65yearsofhumanadenovirusseroprevalence AT oceaneparis areviewof65yearsofhumanadenovirusseroprevalence AT alineraissaouoba areviewof65yearsofhumanadenovirusseroprevalence AT sofiasalazararenas areviewof65yearsofhumanadenovirusseroprevalence AT sodiomonbsirima areviewof65yearsofhumanadenovirusseroprevalence AT guyrtakoudjoudzomo areviewof65yearsofhumanadenovirusseroprevalence AT amidoudiarra areviewof65yearsofhumanadenovirusseroprevalence AT isidorettraore areviewof65yearsofhumanadenovirusseroprevalence AT dramanekania areviewof65yearsofhumanadenovirusseroprevalence AT karsteneichholz areviewof65yearsofhumanadenovirusseroprevalence AT ericaweaver areviewof65yearsofhumanadenovirusseroprevalence AT edouardtuaillon areviewof65yearsofhumanadenovirusseroprevalence AT ericjkremer areviewof65yearsofhumanadenovirusseroprevalence AT franckjdmennechet reviewof65yearsofhumanadenovirusseroprevalence AT oceaneparis reviewof65yearsofhumanadenovirusseroprevalence AT alineraissaouoba reviewof65yearsofhumanadenovirusseroprevalence AT sofiasalazararenas reviewof65yearsofhumanadenovirusseroprevalence AT sodiomonbsirima reviewof65yearsofhumanadenovirusseroprevalence AT guyrtakoudjoudzomo reviewof65yearsofhumanadenovirusseroprevalence AT amidoudiarra reviewof65yearsofhumanadenovirusseroprevalence AT isidorettraore reviewof65yearsofhumanadenovirusseroprevalence AT dramanekania reviewof65yearsofhumanadenovirusseroprevalence AT karsteneichholz reviewof65yearsofhumanadenovirusseroprevalence AT ericaweaver reviewof65yearsofhumanadenovirusseroprevalence AT edouardtuaillon reviewof65yearsofhumanadenovirusseroprevalence AT ericjkremer reviewof65yearsofhumanadenovirusseroprevalence |